Cancer Associated Thrombosis and Isoquercetin (CATIQ) (CATIQ)

• ClinicalTrials.gov Identifier: NCT02195232
• Recruitment Status: Active, not recruiting
• First Posted: July 21, 2014
• Results First Posted: November 12, 2019
• Last Update Posted: November 12, 2019
• Sponsor: Jeffrey Zwicker, MD
• Collaborators: Quercegen Pharmaceuticals; National Heart, Lung, and Blood Institute (NHLBI)
• Information provided by (Responsible Party): Jeffrey Zwicker, MD, Beth Israel Deaconess Medical Center

Study Description

Brief Summary:

This research study is evaluating a drug called isoquercetin to prevent venous thrombosis (blood clots), in participants who have pancreas, non small cell lung cancer or colorectal cancer.

Condition or disease	Intervention/treatment	Phase
Thromboembolism of Vein VTE in Colorectal Cancer; Thromboembolism of Vein in Pancreatic Cancer; Thromboembolism of Vein in Non-small Cell Lung Cancer	Drug: Isoquercetin	Phase 2; Phase 3

Detailed Description:

• This research study is a Phase II/III clinical trial.

  --The goal of this trial is to evaluate if isoquercetin can prevent blood clots in patients with pancreas, non small cell lung cancer or colorectal cancer. In the Phase II part of this study, the investigators are looking for the dose of isoquercetin to reduce D-dimer and demonstrate safety.

• Phase III Endpoint and Treatment Plan

  • Primary Endpoint for Phase III portion of protocol: Cumulative incidence of VTE.
  • Following the completion of the phase II portion, enrolled patients will be randomized 1:1 to Arm C (isoquercetin) or Arm D (placebo). The dose for Arm C will be determined after evaluation of the Phase II portion of the trial. The protocol will be amended when the decision is made whether to proceed to Phase III and what dose to use for Arm C. The study will be double-blinded to treatment arm. Lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days.
  • At BIDMC, optional blood draw will be performed at time 0 and 4 hours following the first dose of study drug.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 64 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients.
• Actual Study Start Date: January 2015
• Actual Primary Completion Date: December 2018
• Estimated Study Completion Date: April 2023

Arms and Interventions

Arm	Intervention/treatment
Experimental: Cohort A - Isoquercetin; -- Cohort A: 500 mg, Once daily, 28 days - For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days.	Drug: Isoquercetin; Other Names: quercetin-3-O-glucoside; 482-35-9
Experimental: Cohort B - Isoquercetin; --Cohort B: 1000 mg, Once daily, 28 days - For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days.	Drug: Isoquercetin; Other Names: quercetin-3-O-glucoside; 482-35-9

Outcome Measures

Primary Outcome Measures :

1. Percent Change in D-dimer Value [ Time Frame: Baseline, 56 Day ]
   D-dimer concentrations will be compared for each patient at day 0 and day 56 by a paired-t test analysis. Analysis will be performed on an intention to treat basis for patients who undergo randomization and completed the baseline and day 56 D-dimer assessments.

Secondary Outcome Measures :

1. Number of Participants With Hemorrhage [ Time Frame: study visits until day 56 ]
   Investigating the safety of isoquercetin in cancer patients
2. Cumulative Incidence of VTE at 56 Days [ Time Frame: 56 days ]
   To investigate the cumulative incidence of VTE according to tissue factor bearing microparticle status (and isoquercetin randomization).

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Participants must meet the following criteria on screening examination to be eligible to participate in phase 2 and 3 of the study:
• Participants must have histologically confirmed malignancy that is metastatic or currently unresectable.

• Eligible malignancies include:

  • Adenocarcinoma of the pancreas (currently unresectable or metastatic)
  • Colorectal (stage IV)
  • Non-small cell lung cancer (currently unresectable stage III or stage IV)
• Receiving or scheduled to receive first or second line chemotherapy (within 30 days of registration)
• Minimum age 18 years. Because limited dosing or adverse event data are currently available on the use of isoquercetin in participants <18 years of age, children are excluded from this study but will be eligible for future pediatric isoquercetin trials.
• Life expectancy of greater than 4 months.
• ECOG performance status ≤2 (see Appendix B ).
• Patient must be able to swallow capsules (phase III only)

• Participants must have preserved organ and marrow function as defined below:

  • Absolute neutrophil count ≥1,000/mcL
  • Platelets ≥ 90,000/mcL
  • PT and PTT ≤ 1.5 x upper limit of normal
  • Total bilirubin < 2.0 mg/dl
  • AST (SGOT)/ALT (SGPT) ≤ 2.5 X institutional upper limit of normal Creatinine < 2.0 mg/dl
• The effects of isoquercetin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Participants may not be receiving any other study agents.
• Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
• Prior history of documented venous thromboembolic event within the last 2 years (excluding central line associated events whereby patients completed anticoagulation).
• Active bleeding or high risk for bleeding (e.g. known acute gastrointestinal ulcer)
• History of significant hemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 24 months
• Familial bleeding diathesis
• Known diagnosis of disseminated intravascular coagulation (DIC)
• Currently receiving anticoagulant therapy
• Current daily use of aspirin (>81mg daily), Clopidogrel (Plavix), cilostazol (Pletal), aspirin-dipyridamole (Aggrenox) (within 10 days) or considered to use regular use of higher doses of non-steroidal anti-inflammatory agents as determined by the treating physician (e.g ibuprofen > 800 mg daily or equivalent).
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Known intolerance of niacin or ascorbic acid (including known G6PD deficiency)
• Pregnant women are excluded from this study because isoquercetin is a PDI inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with isoquercetin, breastfeeding should be discontinued if the mother is treated with isoquercetin. These potential risks may also apply to other agents used in this study.

Contacts and Locations

Locations

United States, California

USC/Norris Comprehensive Cancer Center

Los Angeles, California, United States, 90033

VA Northern California Health Care System

Sacramento, California, United States, 95655

United States, Connecticut

VA Connecticut Healthcare System

West Haven, Connecticut, United States, 06450

United States, District of Columbia

Veterans Affair Medical Center

Washington, District of Columbia, United States, 20422

United States, Maine

York Hospital-Oncology Treatment Center

York, Maine, United States, 03909

United States, Massachusetts

Boston VA Healthcare System

Boston, Massachusetts, United States, 02130

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

Mount Auburn Hospital

Waltham, Massachusetts, United States, 02138

United States, Missouri

Washington University in St. Louis

Saint Louis, Missouri, United States, 63110

United States, Rhode Island

Providence VA Medical Center

Providence, Rhode Island, United States, 02908

United States, Vermont

White River Junction VA Medical Center

White River Junction, Vermont, United States, 05009

Sponsors and Collaborators

Jeffrey Zwicker, MD

Quercegen Pharmaceuticals

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

• Principal Investigator: Jeffrey Zwicker, MD; Beth Israel Deaconess Medical Center

  Study Documents (Full-Text)

Documents provided by Jeffrey Zwicker, MD, Beth Israel Deaconess Medical Center:

Study Protocol and Statistical Analysis Plan  [PDF] October 27, 2016

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A, Puligandla M, Caughey T, Bauer KA, Kuemmerle N, Wong E, Wun T, McLaughlin M, Hidalgo M, Neuberg D, Furie B, Flaumenhaft R; CATIQ Investigators11. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019 Feb 21;4(4). pii: 125851. doi: 10.1172/jci.insight.125851. eCollection 2019 Feb 21.

• Responsible Party: Jeffrey Zwicker, MD, Principal Investigator, Beth Israel Deaconess Medical Center
• ClinicalTrials.gov Identifier: NCT02195232
• Other Study ID Numbers: 14-114
• First Posted: July 21, 2014
• Results First Posted: November 12, 2019
• Last Update Posted: November 12, 2019
• Last Verified: October 2019

Keywords provided by Jeffrey Zwicker, MD, Beth Israel Deaconess Medical Center:

Venous Thromboembolic Events in Cancer Patients; Thromboembolism of Vein in Colorectal Cancer; Thromboembolism of Vein in Pancreatic Cancer; Thromboembolism of Vein in Non-small Cell Lung Cancer

Additional relevant MeSH terms:

Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Pancreatic Neoplasms; Thromboembolism; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Endocrine System Diseases; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases